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Abstract
The development of end stage renal failure can be 
seen as a catastrophic health event and patients with 
this condition are considered at the highest risk of 
cardiovascular disease among any other patient groups 
and risk categories. Although kidney transplantation 
was hailed as an optimal solution to such devastating 
disease, many issues related to immune-suppressive 
drugs soon emerged and it became evident that 
cardiovascular disease would remain a vexing problem. 
Progression of chronic kidney disease is accom-
panied by profound alterations of mineral and bone 
metabolism that are believed to have an impact on 
the cardiovascular health of patients with advanced 
degrees of renal failure. Cardiovascular risk factors 
remain highly prevalent after kidney transplantation, 
some immune-suppression drugs worsen the risk 
profile of graft recipients and the alterations of mineral 
and bone metabolism seen in end stage renal failure 
are not completely resolved. Whether this complex 
situation promotes progression of vascular calcification, 
a hall-mark of advanced chronic kidney disease, and 
whether vascular calcifications contribute to the poor 
cardiovascular outcome of post-transplant patients is 
reviewed in this article.
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Core tip: Despite partial restoration of glomerular 
function many bone and vascular abnormalities that 
develop during dialysis persist after kidney trans-
plantation. Cardiovascular risk factors are also highly 
prevalent after kidney transplantation and some 
immune-suppressive drugs worsen the risk profile of 
graft recipients. As a result kidney transplant recipients 
continue to demonstrate a high cardiovascular risk in 
part due to the effect of vascular calcification.
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INTRODUCTION
Despite a significant improvement in recent years, 
cardiovascular (CV) morbidity and mortality remain 
highly incident in recipients of kidney transplant. The 
reported annual risk of fatal or non-fatal cardiovascular 
events is 3.5%-5% even after adjustment for traditional 
risk factors[1]. This represents a very high CV risk against 
the 10-year risk benchmark of 20% in the general 
population as stigmatized by the ATP-Ⅲ guidelines[2]. In 
addition to conventional cardiovascular disease (CVD) 
risk factors (such as diabetes, hypertension, obesity, 
smoking and dyslipidemia), several patient and graft 
related factors seem to influence the high incidence of 
cardiovascular events post-transplantation[3,4]. These 
include, among others, the duration of prior dialysis, graft 
function after transplantation, hyperhomocysteinemia, 
elevated inflammatory markers, proteinuria, acute 
rejection episodes, new onset diabetes mellitus post-
transplant, and the toxic effects of immunosuppressant 
drugs. However, the effect of residual bone and mineral 
metabolism abnormalities commonly seen in patients 
with chronic kidney disease (CKD) must also be taken 
into account. Vascular and valvular calcifications feature 
prominently as conditions tied with a poor outcome 
in patients with CKD[5,6]. In this review we discuss 
how persistent alterations of mineral metabolism and 
bone remodeling typical of end stage renal failure may 
affect the long-term CV health of patients after kidney 
transplantation.
CV RISK PROFILE AFTER 
TRANSPLANTATION: TRADITIONAL RISK 
FACTORS 
Diabetes mellitus (DM) is one of the most common 
causes of CKD and dialysis in Western countries and 
carries a high risk of CV complications even after tran–
splantation. New onset DM has been described in 
approximately 25% of non-diabetic kidney-transplant 
recipients years after surgery[7,8]. Immunesupression 
regimen may have a part in inducing new onset DM; 
steroids as well as tacrolimus have been identified as 
agents linked with a high incidence of de-novo DM 
and an associated increased risk of atherosclerotic 
cardiovascular events[9]. An observational analysis 
from the Norwegian Renal Registry that included 201 
consecutive renal allograft recipients demonstrated 
that patients with post-transplant DM have a three-fold 
increased risk of major cardiac events (cardiac death 
or non-fatal myocardial Infarction) compared with non-
diabetic patients (HR = 3.27, 95%CI: 1.22-8.80, p = 
0.019)[10]. Of interest, pre-transplant DM (HR = 5.09, 
95%CI: 2.60-9.96, p < 0.001) and age (HR = 1.03, 
95%CI: 1.01-1.05, p = 0.016), but not post-transplant 
DM (HR = 1.20, 95%CI: 0.58-2.49, p = 0.621), were 
independent predictors of death in the multivariable 
regression model.
Recent estimates assess the prevalence of hyperten-
sion in post-renal transplant recipients at 40%-90%[11]. 
The prevalence is particularly high in the first 3 mo after 
surgery, but it appears to remain elevated even after 
the first and second year after surgery[12]. In a recent 
report[11], hypertension persisted despite a definite 
improvement in serum urea and creatinine levels and 
progressive increase in urinary volume. Hypertension 
in the post-renal transplant patients carries a greater 
risk of cardiovascular events and death than it does 
in the general population and it plays a major role in 
the chronic deterioration of graft function[13]. Many 
factors may contribute to the development of post-
transplant hypertension; among others the use of 
immunosuppressive drugs, donor-recipient mismatch, 
hypercalcemia and recurrence of glomerular nephritis[13]. 
Dyslipidemia is mainly characterized by increased 
levels of triglycerides and low levels of apoA1 associated 
lipoproteins (namely HDL) while LDL levels, a well-
established risk factor for CVD in the general population, 
are not typically elevated or only mildly elevated. 
Immunosuppressive drugs can adversely affect a patient’s 
lipid profile in the post-transplantation period. Steroids 
can cause insulin resistance and hyperinsulinemia with 
the attendant dyslipidemia[14]. Cyclosporine has been 
known to decrease hepatic clearance of LDL as well 
as increase the synthesis of VLDL and decrease the 
secretion of bile salts[15]. Mammalian target of rapamycin 
(mTOR) inhibitors reduce the activity of circulating 
lipases and decrease fatty acids uptake into the adipose 
tissue leading to a decrease in plasma lipid clearance[16]. 
All of these mechanisms contribute to an increase in 
the serum level of various lipoprotein subfractions. 
Statins lower CV morbidity and mortality in patients with 
early stages of CKD, have little or no effect in patients 
receiving dialysis[17], and have uncertain effects in kidney 
transplant recipients[18]. Based on limited available data 
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such as the ALERT study[19], the members of the KDIGO 
panel on dyslipidemia recommended use of statins in 
renal transplant recipients (weak recommendation with 
moderate quality of evidence)[20].
Approximately 25% of renal transplant recipients 
are smokers. Tobacco use is an independent risk factor 
for CVD and confers a 30% risk of graft loss as a con-
sequence of early CVD[21]. Of note, smoking has been 
shown to confer a risk of death with a functioning graft 
as great as DM[22]. Smoking cessation can reverse the 
risk; patients who stopped smoking for at least 5 years 
prior to transplantation had a 34% risk reduction in CV 
events[23]. Thus, physicians are expected to provide a 
strong recommendation for smoking cessation prior to 
transplantation[24].
IMMUNOSUPPRESSIVE DRUGS
Endothelial cells play a vital role in the success or failure 
of a transplant graft. As a result of a succession of insults 
suffered during explantation and reimplantation the 
inflammatory cascade is triggered and may activate 
the proliferative and fibrotic processes characteristic of 
chronic graft vasculopathy. Immunosuppressive drugs 
are used to minimize acute rejection and maximize 
graft survival although they have the potential to induce 
nephrotoxicity and increase CV risk. Of note, episodes 
of acute rejection have been reported as an additional 
risk factor for incident CV events post-transplantation[3]. 
As discussed previously, corticosteroids and calcineurin 
inhibitors (CNIs) can promote or aggravate the severity 
of hypertension, induce lipid abnormalities and transplant 
related DM. The main cardiovascular toxicity of steroids 
and CNIs is inhibition of inducible nitric oxide, thus 
promoting endothelial dysfunction, one of the first steps 
in the development of atherosclerosis[25]. mTOR inhibitors 
have different vascular effects. Rapamycin inhibits 
smooth muscle cells proliferation, while everolimus 
impairs the vasoactive and antithrombotic function of 
endothelial cells[26]. 
NONTRADITIONAL RISK FACTORS: 
BIOMARKERS OF BONE AND MINERAL 
DISORDERS 
Bone and mineral disorders are frequent in patients 
who have undergone kidney transplantation[27]. Pre-
existing alterations of mineral metabolism and bone 
remodeling acquired during CKD progression and 
dialysis, such as hyperparathyroidism, often persist 
and are compounded by the effects of immunosup-
pressive agents. Typical laboratory abnormalities post-
transplant include hypercalcemia and hyphosphatemia. 
Hypercalcaemia is a severe complication reported in 
up to 53% of kidney transplant patients that can affect 
graft function both acutely, owing to vasoconstriction, 
and chronically by mediating calcification of the tubulo-
interstitium[28-30]. Hypercalcemia can also increase the 
risk of soft-tissue and vascular calcification, which in 
turn can adversely affect patients’ outcome[31]. In kidney 
transplant recipients persistent hyperparathyroidism is 
largely dependent on parathyroid gland hyperplasia. 
Parathormone (PTH) enhances calcium re-absorption 
and phosphorus excretion leading to hypercalcemia 
and hypophosphatemia[32]. In addition, the restoration 
of active vitamin D [1,25(OH)2D] synthesis by the 
transplanted kidney and the progressive improvement of 
skeletal resistance to PTH may accelerate hypercalcemia. 
The negative impact of hypercalcemia and persistent 
secondary hyperparathyroidism (SHP) on outcome 
of transplanted patients has been demonstrated in 
several observational studies. Altered calcium and PTH 
homeostasis have been linked to renal calcinosis and 
loss of graft function as documented by serial biopsies in 
a cohort of 213 patients[29]. Persistent SHP is associated 
with a poor prognosis in kidney transplant recipients. 
Bleskestad et al[33] reported that high PTH levels (greater 
than the fourth quartile, > 14.4 pM) were associated 
with a significant 2.6 fold increase (HR = 2.60, 95%CI: 
1.10-6.16, p = 0.03) in the risk of the composite 
endpoint of all-cause mortality, cardiovascular events 
and graft loss, independent of confounders. 
Hypophosphataemia is very common and is seen 
in the majority (> 90%) of transplant recipients 3 mo 
after transplantation. Although it is usually seen shortly 
after transplantation, phosphate levels may remain 
low for longer than a year prost-transplantation[34]. Per-
sistent hyperparathyroidism is not the only mechanism 
subtending post-transplantation hypophosphatemia 
and fibroblast growth factor 23 (FGF-23) may play an 
important role as well[35]. FGF-23 levels increase early 
and continue to rise with CKD progression in an attempt 
to maintain serum phosphorus levels in the normal 
range. FGF-23 is mainly synthesized by osteocytes and 
is involved in the bone-kidney axis and the regulation of 
calcium phosphate metabolism. It acts primarily on the 
proximal renal tubule as a phosphaturic agent through 
the downregulation of sodium-phosphate co-transporters. 
Additionally, it blocks the generation of 1,25(OH)2D 
through inhibition of the renal 1-alpha-hydroxylase 
enzyme and stimulation of the 24-hydroxylase enzyme 
that is responsible for the degradation of activated 
vitamin D[36]. Through down-regulation of production of 
1,25(OH)2D, FGF-23 can also promote the development 
of secondary hyperparathyroidism[37]. Investigators 
have suggested that some patients develop a syndrome 
of tertiary FGF-23 hypersecretion post-transplant that 
may justify their persistent hypophosphatemia[38,39]. 
FGF-23 has been independently associated with risk of 
all-cause death, heart failure and cardiovascular events 
in dialysis and CKD patients[40]. Available data, also 
suggest that elevated levels of FGF-23 post-transplant 
are independently associated with all-cause mortality 
and graft loss. In a large prospective cohort of 984 
stable kidney transplant recipients (mean estimated 
glomerular filtration rate 51 ± 21 mL/min per 1.73 
m2), elevated FGF-23 levels (median level 28 RU/mL; 
interquartile range: 20-43 RU/mL) were independently 
D’Marco L et al . Bone and vascular health after kidney transplant
225 December 24, 2015|Volume 5|Issue 4|WJT|www.wjgnet.com
associated with a significantly increased risk of all-cause 
mortality and graft loss (adjusted HR = 1.46 per SD 
increase in log FG-F23, 95%CI: 1.28-1.68, p < 0.001). 
Notably, the results were similar for each components 
of the composite endpoint and, at least in this study 
cohort, none of the other biomarkers of CKD-MBD were 
linked with the outcome of interest after adjustment for 
confounders[41].
RENAL OSTEODYSTROPHY AFTER 
KIDNEY TRANSPLANTATION: 
PECULIARITIES AND CLINICAL 
RELEVANCE
As discussed above, SHP persists in many cases after 
renal transplantation[42]. Parathyroid glands from 
transplant recipients show increased expression of both 
vitamin D and calcium sensing receptors when compared 
to glands from patients on maintenance dialysis, indi-
cating an increased sensitivity to circulating levels of 
vitamin D and calcium. Importantly, persistent SHP is a 
major determinant of bone disease in the post-transplant 
period. Although bone histology has been reported 
rarely in these patients, limited evidence suggests that 
bone histologic parameters are mostly abnormal. The 
prevailing findings are reduced bone volume, low bone 
turnover and generalized or focal defective mineralization 
(osteomalacia)[43]. Biochemical markers like PTH and 
alkaline phosphatase are of limited diagnostic utility to 
recognize the presence of bone disease[44]. Similarly, 
the information obtainable with non-invasive radiologic 
techniques like Dual-energy X-ray absorptiometry 
(DEXA) is weakly correlated with bone histology. As 
an example, in a study that enrolled only patients with 
markedly reduced bone mineral density (BMD), defined 
as a DEXA T-score < 4.0, bone histology confirmed the 
presence of osteoporosis only in 25% of the cases[45]. 
Furthermore, while reduced BMD is a frequent finding 
after renal transplantation, little is known about the 
associated risk of bone fracture. A recent systematic 
review of the literature (10 studies that enrolled 
262678 transplant recipients were included), aiming at 
assessing the incidence and the risk factors associated 
with bone fracture after kidney transplant, concluded 
that incidence rates ranged from 3.3 to 99.6 fractures 
per 1000 person-years (5-year cumulative incidence: 
0.85%-27%), depending on fracture site and case-mix. 
Common factors linked with increased fracture risk were 
older age, female sex, diabetes mellitus, dialysis duration 
before transplantation, previous history of fracture and 
cadaveric kidney (vs living) donor[46]. Unfortunately, poor 
consensus on data reporting in different studies hampers 
a more accurate assessment of the relationship between 
fracture rate and risk factors post-transplantation. 
Immunosuppressive drugs contribute to bone disease. A 
recent publication described a decrease in the incidence 
of hip fractures in more recent years, with a potential 
positive influence on this favorable trend exerted by 
improved immunosuppressive strategies[47]. The case-
mix adjusted HR for hip fracture was 0.56 (95%CI: 
0.47-0.99) in 2010 compared to 1997; when the model 
was adjusted for baseline immunosuppressive therapy 
the HR increased slightly to 0.68 (95%CI: 0.47-0.99), 
suggesting that part of the effect may be attributable 
to post-transplant immunosuppressive regimens. Of 
interest, the observed 30-d mortality risk after a hip 
fracture was relatively low when compared to the 
general population (event rate: 2.2 per 100 events, 
95%CI: 1.3-3.7)[48] possibly reflecting the younger age 
of the study subjects (median age 51 years) and/or 
the favorable trend toward hip fracture reduction. In 
summary, transplant recipients, like advanced CKD 
and dialysis patients, suffer from persistent renal osteo-
dystrophy that is linked with morbidity and mortality 
risk. 
BONE-VASCULAR AXIS AND VASCULAR 
CALCIFICATION IN TRANSPLANTS 
PATIENTS
In recent years there has been an increasing appreciation 
of the existence of a “bone-vascular axis”. This term refers 
to the existence of a bidirectional flow of information 
between bone and vessels through exchange of cells, 
hormones and other metabolic signals[49]. Although a 
close bone-vascular interaction is present in the general 
population, it is particularly active in CKD patients[50], 
and very likely in kidney transplant recipients. Inves-
tigators proposed that promoters and inhibitors of 
bone mineralization, such vitamin D, PTH, phosphorus, 
fetuin-A, matrix-Gla protein and others, are also involved 
in the pathogenesis of vascular calcification[51]. FGF-23 
has been linked with increased mortality and graft 
loss after kidney transplantation[41], but its role as a 
promoter of vascular calcification warrants further 
elucidation. Drugs with immunosuppressive activity may 
modulate the expression, regulation, and function of 
the RANKL, RANK, and OPG system both at the skeletal 
and vascular level. In particular, sirolimus inhibits 
osteoclast formation, steroids can induce apoptosis of 
osteoblasts and osteocytes, and reduce osteoblast 
replication and differentiation[25,52]. However, current 
data are limited and at times conflicting. For instance, 
experimental studies suggest that mycofenolate mofetil 
inhibits vascular smooth cells proliferation and improves 
endothelial dysfunction when compared to steroids 
or calcineurin inhibitors[26]. Similarly, mTOR inhibitors 
(rapamycin and everolimus) interfere with vascular 
smooth muscle cells proliferation and endothelial cell 
function[51]. These observations may explain the results 
documented by Nguyen et al[53] of a protective role of 
mycofenolate mofetil on aortic calcification in recipients 
of kidney allografts. Nonetheless, the concomitant 
effect of various immunosuppressive drugs on lipid 
metabolism, diabetes mellitus, and hypertension may 
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also have a negative impact on the cardiovascular health 
of transplant recipients. The available evidence is too 
limited to clearly establish and disentangle the relative 
influence of single factors on the bone-vascular axis.
A few studies tested the impact of renal function 
restoration via kidney transplantation on vascular 
calcification and yielded conflicting results (Table 1). 
The comparability and generalizability of these study 
results is hampered by the small sample size, the lack 
of a consensus on how to evaluate vascular calcification 
progression, the difference in follow-up time between 
studies, and the lack of control groups with comparable 
degrees of baseline renal dysfunction and calcification 
burden. Hence the results must be interpreted in 
the context of a considerable heterogeneity of data 
collection and interpretation. In a preliminary observation 
of 23 kidney transplant recipients and 17 chronic 
hemodialysis patients submitted to sequential chest 
computed tomography scans, Moe et al[54] reported 
an almost complete arrest of coronary artery calcium 
(CAC) progression in post-transplant patients and 
continued accrual of calcium in patients on dialysis, 
over a follow-up period of 15-20 mo. However, while 
no new calcium deposition was noted in individuals free 
of calcification at baseline, a trend toward an increase 
in aortic calcification was noted in transplant recipients 
and controls. A few subsequent studies showed that 
cardiovascular calcification continues to progress after 
kidney transplantation (Table 1), although this may 
occur at a slower rate than in patients receiving dialysis. 
Mazzaferro et al[55] reported an annual CAC change 
among individuals with baseline CAC > 15 Agatston 
units of 8.8% and 31.0% in transplanted patients 
and controls, respectively. Deregulation of bone and 
mineral metabolism pathways probably contribute 
to the continued deposition of calcium in soft tissues 
even after transplantation. Mazzaferro et al[55] showed 
an independent association of serum PTH and CAC 
progression in a study that enrolled 41 transplant 
recipients and 31 dialysis patients, independent of the 
use of vitamin D. In a series of 197 patients, Maréchal 
et al[56] reported an independent association of CAC 
and aortic calcium score progression with history of 
prior cardiovascular disease, presence of calcification at 
study inception, use of statins, serum levels of vitamin 
D and serum phosphate levels (median annualized 
score progression: 11, interquartile range: 1-58 and 5, 
interquartile range: 0-62 mg respectively). Of interest, 
there was no evidence of vascular calcification regression 
after transplantation in any of these three studies.
Finally, Seyahi et al[57] described a CAC prevalence 
of 35.3% in 150 kidney transplant recipients (median 
Ref. Size Follow-up Main findings
Risk factors associated with vascular calcification progression in KTR
Maréchal et al[56], 2012 281 enrolled, 197 analyzed 4.4 yr CAC increase: 11%/yr
AoC increase: 4%/yr
Risk factors for CAC progression: Baseline CAC, history of CVD, statin use, 25OH 
vit D levels
Risk factors for AoC progression: Baseline AoC, higher pulse pressure, statin 
therapy, older age, serum phosphate level, use of aspirin, and male sex
Mazzaferro et al[55], 2009 41 KTR compared to 31 
matched dialysis patients
  2 yr KTR blunts but does not halt CAC progression (12.2% vs 56.6% CAC progression in 
KTR vs  dialysis patients)
Factors associated with CAC progression: Parathyroid hormone serum levels, 
modality of renal replacement therapy (dialysis vs  transplantation), erythrocyte 
sedimentation rate
Seyahi et al[57], 2012 150 prevalent KTR without 
history of CVD
2.8 yr Baseline CAC prevalence 35.3% (mean CAC: 60 ± 174)
Follow-up: CAC prevalence 64.4% (mean CAC: 94 ± 245)
Individual CAC progression: 28%-38%
Median annualized CAC progression 11 Agatston Units
Factors associated with CAC progression: Baseline CAC, high triglyceride levels, 
biphosphonate therapy
Prognostic relevance of vascular calcification in KTR
Roe et al[61], 2010 112 asymptomatic incident 
KTR without history of CVD
  6 yr Median CAC at study inception 70 (33% of patients had no CAC)
CAC was associated with increased risk of the composite endpoint of coronary 
artery bypass surgery, percutaneous intervention or myocardial infarction, 
cerebrovascular accident or peripheral arterial disease (revascularization or 
amputation), and all-cause mortality. Per 100 unit increase in CAC: HR = 1.05, 
95%CI: 1.00-1.11; P = 0.045
Nguyen et al[62], 2010 281 enrolled 2.3 yr CAC independent predictor of the composite endpoint of cardiovascular death, 
myocardial infarction, stroke or transient ischemic attack and revascularization. For 
a 2.72 fold increase in CAC, HR = 1.40, 95%CI: 1.12-1.75, for a 2.72-fold increase in 
CAC, P < 0.0031
Table 1  Summary of findings of prospective studies that investigated the progression of coronary artery calcium and aortic calcium 
after kidney transplantation, and studies that assessed the prognostic significance of coronary artery calcium after transplantation; all 
imaging studies were performed with cardiac computed tomography
1The hazards ratios is calculated for a 2.72 times increase in coronary artery calcification on a natural log scale. CAC: Coronary artery calcium score; AoC: 
Aorta calcium score; CVD: Cardiovascular disease; KTR: Kidney transplant recipient.
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time from transplantation: 83 mo, interquartile range 
31-269 mo) without prior history of cardiovascular 
disease. During an average follow-up of 2.8 years, CAC 
progression ranged from 28%-38% (median annual CAC 
progression: 11.1%, interquartile range: -51.5 to 185.5). 
Notably, 34 (35.0%) individuals with evidence of CAC at 
study conclusion were free from CAC at study inception 
(incidence rate 12.5%/year). Finally, CAC regression was 
documented in only 2 patients (1.3%). Independent 
predictors of progression were serum triglycerides levels 
(OR per mg/dL increase: 1.007, 95%CI: 1.002-1.012), 
presence of CAC at baseline (OR = 5.23, 95%CI: 
1.93-14.19), and use of bisphosphonates (OR = 2.64, 
95%CI: 1.04-6.68)[57]. In this case bisphosphonates 
use may have been a confounder by indication; that is, 
patients with the worst degree of bone disease - likely 
associated with parallel vascular disease - received 
bisphosphonates. 
Other smaller studies[58-60] investigated vascular 
calcification prevalence and progression in kidney tra-
nsplant recipients yielding conflicting results on the 
impact of kidney transplantation and renal function 
restoration on accumulation of vascular calcification and 
its progression.
As shown in the general population and maintenance 
dialysis patients, vascular calcification per-se has been 
associated with an unfavorable outcome in transplant 
recipients. In a cohort of 112 incident transplant reci-
pients without history of cardiovascular disease, each 
100 unit increase in CAC score was associated with 
a 5% (HR = 1.05, 95%CI: 1.00-1.11; p = 0.045) 
increased risk of death or major cardiovascular 
events 6 years after surgery[61]. Similarly, in a larger 
cohort of 281 transplant recipients without history of 
cardiovascular disease, Nguyen et al[62] documented an 
independent association of baseline CAC score and the 
risk of a composite endpoint of cardiovascular death, 
myocardial infarction, coronary, revascularization, 
stroke and transient ischemic attack (p < 0.003). No 
data are available yet to associate the progression of 
cardiovascular calcification and outcome in recipients of 
a kidney transplant.
FUNCTIONAL VASCULAR CHANGES
Increased arterial stiffness can be measured non-
invasively by tonometry or ultrasound based methods. 
The etiopathogenesis is multifactorial and includes 
atherosclerosis, myocytes apoptosis and degradation 
of collagen fibers in the media as well as accumulation 
of calcium in the intima and media layers of the vessel 
wall. Hence, although vascular stiffness has been seen 
as a surrogate marker of vascular calcification it is not 
merely dependent on this pathological process. Current 
evidence supports the notion that a successful kidney 
transplantation is associated with an improvement in 
indices of compliance of large [i.e. pulse wave velocity 
(PWV)] and peripheral-muscular [i.e. augmentation 
index (AIx)] arteries[63,64]. While epidemiological studies 
in the general population and CKD patients suggest a link 
between arterial stiffness and bone health, the relative 
contribution of renal function restoration and amelio-
ration of bone mineral abnormalities to vascular stiffness 
improvement after kidney transplantation remains 
unclear. Indeed, PWV and AIx improve very quickly 
after surgery at a time when bone mineral metabolism 
abnormalities cannot have been reversed yet. Therefore, 
functional vascular parameters possibly improve as a 
consequence of the partial restoration of glomerular 
function following kidney transplantation[65]. As in CKD 
subjects[66,67], it is unclear whether an increase in arterial 
stiffness is a promoter or a consequence of progressive 
renal function decline[68,69]. In a prospective cohort study 
of 101 subjects receiving a functional graft, glomerular 
filtration rate decline was associated with smoking and 
acute rejection episodes in the first year after surgery, 
while it was associated with donor age and aortic stiffness 
after the first year from transplantation[69]. Among 45 
normotensive kidney donors the compensatory hyper-
filtration response to renal mass loss was reduced in 
donors with increased aortic stiffness prior to organ 
explant[68]. These results suggest a vicious cycle in which 
chronic kidney disease may induce arterial wall changes 
and stiffening that in turn promote loss of renal function. 
Although mostly based on studies of limited sample 
size, several factors have been linked with arterial 
dysfunction and stiffness in kidney transplant recipients. 
Traditional CV risk factors[70,71] as well as specific risk 
factors such as immunosuppressive regimens[72] or ab-
normalities of bone and mineral metabolism[73,74] have 
been linked with changes in arterial wall stiffness. In a 
series of 47 kidney transplant patients, increased bone 
turnover (assessed by serum levels of bone alkaline 
phosphatase, osteocalcin, beta-crosslaps) was associated 
with elevated PWV, during the first 24 mo after 
surgery[74]. In another cross-sectional study of 89 renal 
transplant patients PVW, but not Aix, was associated 
with elevated serum levels of 1,25 vitamin D and 
osteoprotegerin, further corroborating the notion of a 
bone-vascular cross-talk[73]. Although some authors have 
investigated changes in PWV and ankle brachial index 
before and after kidney transplantation as a surrogate for 
vascular calcification, these measures are only indirectly 
linked and may be responsible for adverse outcomes 
based on different mechanisms. In a prospective study 
of 253 transplanted patients, both aortic calcification (HR 
per 1 unit increase in the aortic calcification score: 1.09, 
95%CI: 1.02-1.17) and PWV (HR per 1 m/s increase: 
1.45, 95%CI: 1.16-1.80) independently predicted the 
occurrence of any cardiovascular events during a 36 mo 
follow-up[75]. 
CONCLUSION
Current evidence suggests that mineral and bone 
disorders persist in large degree after successful 
kidney transplantation. Alterations of mineral and 
bone metabolism most likely contribute to vascular 
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calcification progression. Although data are scarce 
and heterogeneous, renal function restoration does 
not seem to halt vascular calcification. Available data 
suggest that CAC progresses at similar or at best at a 
slightly attenuated rate in transplant patients compared 
to dialysis patients. As a marker of vasculopathy[76], 
vascular calcification is associated with an increased risk 
of unfavorable events in kidney transplant recipients, 
as previously shown in the general population and CKD 
patients. These observations underline the importance 
of considering the post-transplant state as a state 
of persistent moderate kidney dysfunction with the 
attendant disorders of mineral metabolism and bone 
remodeling. In fact, the glomerular filtration rate after 
a single successful kidney transplantation tipically 
averages about half that of a patient with normal renal 
function. This situation varies greatly according to the 
age of the recipient and donor, the condition of the graft 
at the time of anastomosis (fully functional vs marginal 
status graft) and the prior cardiovascular risk level and 
control of risk factors in the recipient. A selection bias 
should also be considered while analysing the data from 
the literature, as only patients with the best risk profile 
and the lowest amount of iliac calcification (and likely 
systemic calcification) are added to the transplant lists. 
Whether a careful management of bone and mineral 
metabolism with new therapeutic advances will improve 
the cardiovascular risk of transplant recipients remains 
to be verified in future studies.
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